KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Expenses (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Accumulated Expenses for 13 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 45.65% to $14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, up 45.65% year-over-year, with the annual reading at $14.5 million for FY2025, 45.65% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $14.5 million at Xenon Pharmaceuticals, up from $11.1 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $14.5 million in Q4 2025, with the low at $1.3 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $6.1 million, with a median of $5.8 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses dropped 1.97% in 2022, then skyrocketed 165.57% in 2025.
  • Over 5 years, Accumulated Expenses stood at $5.9 million in 2021, then fell by 1.97% to $5.8 million in 2022, then increased by 27.51% to $7.4 million in 2023, then skyrocketed by 33.71% to $9.9 million in 2024, then skyrocketed by 45.65% to $14.5 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $14.5 million, $11.1 million, and $8.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.